1-Hydroxybenzotriazole → Boc-Glu(OtBu)-Ser(tBu)-Asn-Gly

HRID 2407054노트

반응식

HRID 2407054 반응식
C1C=CC2N([OH:10])N=NC=2C=1.[NH:11]1CCC[CH2:13][CH2:12]1.C[N:18]([CH:20]=[O:21])[CH3:19].[NH:22]([C:31](OCC1C2C(=CC=CC=2)C2C1=CC=CC=2)=[O:32])[C@H:23]([C:28]([OH:30])=[O:29])CC(=O)N.[NH:48]([C:59]([O:61]CC1C2C(=CC=CC=2)C2C1=CC=CC=2)=O)[C@H:49](C(O)=O)[CH2:50][O:51][C:52]([CH3:55])([CH3:54])[CH3:53].[NH:76]([C:90]([O:92][C:93]([CH3:96])([CH3:95])[CH3:94])=[O:91])[C@H:77](C(O)=O)[CH2:78][CH2:79][C:80](=[O:86])[O:81][C:82]([CH3:85])([CH3:84])[CH3:83]>CN(C=O)C>[NH:76]([C:90]([O:92][C:93]([CH3:94])([CH3:95])[CH3:96])=[O:91])[C@H:77]([C:59]([NH:48][C@H:49]([C:20]([NH:18][C@H:19]([C:31]([NH:22][CH2:23][C:28]([OH:30])=[O:29])=[O:32])[CH2:13][C:12](=[O:10])[NH2:11])=[O:21])[CH2:50][O:51][C:52]([CH3:53])([CH3:54])[CH3:55])=[O:61])[CH2:78][CH2:79][C:80](=[O:86])[O:81][C:82]([CH3:83])([CH3:84])[CH3:85]

참가 물질

7

반응물 5

HCID 757711-HydroxybenzotriazoleHCID 2724633N-(9-Fluorenylmethoxycarbonyl)-O-tert-butylserineHCID 2724774FMOC-L-asparagineHCID 6993432(2S)-5-(tert-butoxy)-2-{[(tert-butoxy)carbonyl]amino}-5-oxopentanoic acidHCID 23501187piperidine N,N-dimethylformamide

생성물 1

HCID 131731781Boc-Glu(OtBu)-Ser(tBu)-Asn-Gly

시약·촉매·용매 1

HCID 6228Dimethylformamide용매

반응 조건

온도
25 °C

실험 절차

An amino acid whose amino group had been protected, HOBt (67.6 mg, 0.50 mmol), and DIPCI (77.0 μL, 63.1 mg, 0.50 mmol) were dissolved in DMF (2 mL), and the obtained solution was then activated for 15 minutes. Thereafter, the solution was placed in the solid-phase synthesis column. After stirring at 25° C. for 1 hour, the Fmoc group was treated with a 20% piperidine/DMF solution (2 mL) for 20 minutes for deprotection. These operations were repeated, so that amino acids were successively condensed. As the protected amino acids, Fmoc-Asn (177.2 mg, 0.50 mmol), Fmoc-Ser(tBu) (191.6 mg, 0.50 mmol), and Boc-Glu(OtBu) (151.6 mg, 0.50 mmol) were used. On the solid-phase resin, a 4-residue peptide having a protecting group, Boc-Glu(OtBu)-Ser(tBu)-Asn-Gly (SEQ ID NO: 33), was obtained.

후처리

  1. customThereafter, the solution was placed in the solid-phase synthesis column
  2. customcondensed

출처 및 근거

ORD 기록
ord-3d20b491acde4ba49a4f3deaecaa6d6b
출처 데이터셋
uspto-grants-2014_08
특허 번호
US08809258B2

반응 노트

불러오는 중…